NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report) dropped 4.5% on Tuesday . The stock traded as low as $1.43 and last traded at $1.48. Approximately 33,642 shares traded hands during trading, a decline of 29% from the average daily volume of 47,714 shares. The stock had previously closed at $1.55.
NeuroBo Pharmaceuticals Stock Performance
The firm has a 50-day moving average of $1.81 and a two-hundred day moving average of $2.41.
Institutional Investors Weigh In On NeuroBo Pharmaceuticals
A hedge fund recently bought a new stake in NeuroBo Pharmaceuticals stock. Ferguson Wellman Capital Management Inc. bought a new stake in shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Free Report) in the 3rd quarter, according to its most recent filing with the SEC. The institutional investor bought 15,670 shares of the company’s stock, valued at approximately $50,000. Ferguson Wellman Capital Management Inc. owned about 0.19% of NeuroBo Pharmaceuticals at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.37% of the company’s stock.
NeuroBo Pharmaceuticals Company Profile
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
Further Reading
- Five stocks we like better than NeuroBo Pharmaceuticals
- What Do S&P 500 Stocks Tell Investors About the Market?
- NVIDIA Stock Remains Stunningly Undervalued—Here’s Why
- What is a Low P/E Ratio and What Does it Tell Investors?
- Oracle Stock: 5 Reasons This AI Powerhouse Is a Long-Term Buy
- Transportation Stocks Investing
- U.S. Stocks Sink, Foreign Markets Soar: 3 ETFs to Ride the Wave
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
